<SEC-DOCUMENT>0001104659-22-010000.txt : 20220201
<SEC-HEADER>0001104659-22-010000.hdr.sgml : 20220201
<ACCEPTANCE-DATETIME>20220201064527
ACCESSION NUMBER:		0001104659-22-010000
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20220131
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220201
DATE AS OF CHANGE:		20220201

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KIORA PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001372514
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36672
		FILM NUMBER:		22576838

	BUSINESS ADDRESS:	
		STREET 1:		1371 EAST 2100 SOUTH
		STREET 2:		SUITE 200
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84105
		BUSINESS PHONE:		(781) 788-8869

	MAIL ADDRESS:	
		STREET 1:		1371 EAST 2100 SOUTH
		STREET 2:		SUITE 200
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84105

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EYEGATE PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20060811
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm225039d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:KPRX="http://eyegatepharma.com/20220131">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_032_KPRX_eyegatepharma.com_20220131 -->
<!-- Field: Set; Name: xdx; ID: xdx_049_20220131_20220131 -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DEntityCentralIndexKey_0001372514 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-01-31to2022-01-31" name="dei:EntityCentralIndexKey">0001372514</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-31to2022-01-31" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="kprx-20220131.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-01-31to2022-01-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-31</xbrli:startDate>
        <xbrli:endDate>2022-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES<br />
SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, DC 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM&#160;<span id="xdx_90F_edei--DocumentType_c20220131__20220131_zaOwrQEH4Mtg"><ix:nonNumeric contextRef="From2022-01-31to2022-01-31" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT PURSUANT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TO SECTION&#160;13 OR 15(d)&#160;OF THE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of report (Date of earliest event reported):
<b><span id="xdx_903_edei--DocumentPeriodEndDate_c20220131__20220131_zrIsNEmdZoXk"><ix:nonNumeric contextRef="From2022-01-31to2022-01-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">January 31, 2022</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90A_edei--EntityRegistrantName_c20220131__20220131_z78CL3iQfqtl"><ix:nonNumeric contextRef="From2022-01-31to2022-01-31" name="dei:EntityRegistrantName">KIORA PHARMACEUTICALS, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_908_edei--EntityIncorporationStateCountryCode_c20220131__20220131_znSC81xxdoP6"><ix:nonNumeric contextRef="From2022-01-31to2022-01-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of incorporation)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 50%; text-align: center"><b><span id="xdx_902_edei--EntityFileNumber_c20220131__20220131_zxyUmKWcel9h"><ix:nonNumeric contextRef="From2022-01-31to2022-01-31" name="dei:EntityFileNumber">001-36672</ix:nonNumeric></span></b></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 49%; text-align: center"><b><span id="xdx_90E_edei--EntityTaxIdentificationNumber_c20220131__20220131_zuKbtNrn5Jd"><ix:nonNumeric contextRef="From2022-01-31to2022-01-31" name="dei:EntityTaxIdentificationNumber">98-0443284</ix:nonNumeric></span></b></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">(Commission File Number)</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">(IRS Employer Identification No.)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 50%; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90B_edei--EntityAddressAddressLine1_c20220131__20220131_zoxCklN9K3le"><ix:nonNumeric contextRef="From2022-01-31to2022-01-31" name="dei:EntityAddressAddressLine1">1371 East 2100 South</ix:nonNumeric></span></b></p>
                                                                    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90E_edei--EntityAddressAddressLine2_c20220131__20220131_zob8CKYbmwmf"><ix:nonNumeric contextRef="From2022-01-31to2022-01-31" name="dei:EntityAddressAddressLine2">Suite 200</ix:nonNumeric></span> </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><b><span id="xdx_901_edei--EntityAddressCityOrTown_c20220131__20220131_zLhFcMZ6CPIb"><ix:nonNumeric contextRef="From2022-01-31to2022-01-31" name="dei:EntityAddressCityOrTown">Salt Lake City</ix:nonNumeric></span>, <span id="xdx_908_edei--EntityAddressStateOrProvince_c20220131__20220131_zm8404zuK5Yh"><ix:nonNumeric contextRef="From2022-01-31to2022-01-31" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Utah</ix:nonNumeric></span> <span id="xdx_907_edei--EntityAddressPostalZipCode_c20220131__20220131_zjAdf5rYpiD7"><ix:nonNumeric contextRef="From2022-01-31to2022-01-31" name="dei:EntityAddressPostalZipCode">84105</ix:nonNumeric></span></b>&#160;</b></p>
</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 49%; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
                                                                       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
                                                                       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_909_edei--EntityAddressPostalZipCode_c20220131__20220131_ztk7LN97Asn4"><ix:nonNumeric contextRef="From2022-01-31to2022-01-31" name="dei:EntityAddressPostalZipCode">84105</ix:nonNumeric></span></b></p></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">(Address of principal executive offices)</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">(Zip Code)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_903_edei--CityAreaCode_c20220131__20220131_zoDDSrntHRk2"><ix:nonNumeric contextRef="From2022-01-31to2022-01-31" name="dei:CityAreaCode">781</ix:nonNumeric></span>) <span id="xdx_908_edei--LocalPhoneNumber_c20220131__20220131_zaR3y7aEtM1i"><ix:nonNumeric contextRef="From2022-01-31to2022-01-31" name="dei:LocalPhoneNumber">788-9043</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number, including
area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form&#160;8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_901_edei--WrittenCommunications_c20220131__20220131_zoXyL0TRCP3h"><ix:nonNumeric contextRef="From2022-01-31to2022-01-31" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span>&#160;&#160;&#160; Written communications pursuant to Rule&#160;425
under the Securities Act (17 CFR 230.425)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_90B_edei--SolicitingMaterial_c20220131__20220131_zHfA86yI5c1l"><ix:nonNumeric contextRef="From2022-01-31to2022-01-31" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span>&#160;&#160;&#160; Soliciting material pursuant to Rule&#160;14a-12
under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_908_edei--PreCommencementTenderOffer_c20220131__20220131_z5aDA9rjZ8sa"><ix:nonNumeric contextRef="From2022-01-31to2022-01-31" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></span>&#160;&#160;&#160; Pre-commencement
communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_905_edei--PreCommencementIssuerTenderOffer_c20220131__20220131_zbumzzY6wqO2"><ix:nonNumeric contextRef="From2022-01-31to2022-01-31" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></span>&#160;&#160;&#160; Pre-commencement
communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 31%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Title&#160;of&#160;each&#160;class:</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 23%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Trading&#160;Symbol(s)</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 43%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered:</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_edei--Security12bTitle_c20220131__20220131_z4rJ4b1sbAUk"><ix:nonNumeric contextRef="From2022-01-31to2022-01-31" name="dei:Security12bTitle">Common Stock, $0.01 par value</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_edei--TradingSymbol_c20220131__20220131_z5N3VTRn5Py7"><ix:nonNumeric contextRef="From2022-01-31to2022-01-31" name="dei:TradingSymbol">KPRX</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">The <span id="xdx_909_edei--SecurityExchangeName_c20220131__20220131_zZIyIMzjMfSj"><ix:nonNumeric contextRef="From2022-01-31to2022-01-31" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities
Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_901_edei--EntityEmergingGrowthCompany_c20220131__20220131_z7dp7iKOYy26"><ix:nonNumeric contextRef="From2022-01-31to2022-01-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family: Wingdings"><span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 5.02.</b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Appointment of Director</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 31, 2022, the Board of Directors (the
&#8220;Board&#8221;) of Kiora Pharmaceuticals, Inc. (the &#8220;Company&#8221;) appointed Erin Parsons as a member of the Board. Ms. Parsons
will serve as a Class III director and will serve until the Company&#8217;s 2024 Annual Meeting of Stockholders and until her respective
successor is duly elected and qualified or her earlier resignation or removal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board has determined that Ms. Parsons is independent
under the rules of The Nasdaq Capital Market. As a non-employee director of the Company, Ms. Parsons will receive compensation in
the same manner of the Company&#8217;s other non-employee directors, as described in the section entitled &#8220;Director Compensation&#8221;
in the Definitive Proxy Statement on Schedule 14A for the Company&#8217;s 2021 Annual Meeting of Stockholders filed with the Securities
and Exchange Commission on April 30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ms. Parsons, age 46, has served as Founder and
President of Parsons Medical Communications, LLC, an agency providing scientific and strategic consulting to small and large companies
in the ophthalmic space, since its founding in 2010. Ms. Parsons has served as a member of the board of directors of Alimera Sciences,
Inc. (Nasdaq: ALIM), a pharmaceutical company concerned with retinal health and vision, since December 2021. Ms. Parsons received a BS
in Biology from Wake Forest University.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">There
are no arrangements or understandings between </span>Ms. Parsons and any other person pursuant to which Ms. Parsons was appointed as a
director of the Company, and there are no family relationships between Ms. Parsons and any director or executive officer of the Company.
Since the beginning of the Company&#8217;s last fiscal year, the Company has not engaged in any transactions, and there are no proposed
transactions, or series of similar transactions, in which Ms. Parsons was or is to be a participant and in which any related person had
a direct or indirect material interest in which the amount involved exceeds or exceeded $120,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Resignation of Executive Chairman</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective of January 31, 2022, Stephen From voluntarily
resigned as Executive Chairman of the Company and as a member of the Board. Mr. From did not resign as a result of any disagreement regarding
the Company&#8217;s operations, policies or practices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with Mr. From&#8217;s resignation,
the Company and Mr. From entered into a separation agreement (the &#8220;Separation Agreement&#8221;) on January 31, 2022, providing for
severance payments and benefits to Mr. From consistent with the terms of his existing employment agreement with the Company, including
monthly payments of $33,333.33 for eighteen months following the separation date, a lump sum of $300,000 payable on the date of the last
monthly payment, eighteen months of COBRA subsidy payments and eighteen months of accelerated option and restricted stock unit vesting.
The Separation Agreement also includes a release of claims by Mr. From in favor of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing is a summary description of the
terms and conditions of the Separation Agreement and is qualified in its entirety by reference to the Separation Agreement, a copy of
which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Appointment of Chairman</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with Mr. From&#8217;s resignation
as Executive Chairman, effective as of January 31, 2022, the Board appointed Paul Chaney as non-executive Chairman of the Board, and Mr.
Chaney ceased serving as Lead Independent Director upon his appointment as Chairman.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 7.01.</b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulation FD Disclosure.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">On February
1, 2022, the Company issued a press release announcing the&#160;appointment of </span>Ms. Parsons to the Board and Mr. From&#8217;s resignation.
A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The information
furnished herein, including Exhibit 99.1, is not deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise
subject to the liability of that section. This information will not be deemed to be incorporated by reference into any filing under the
Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates them by reference.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1in; font-size: 10pt"><span style="font-size: 10pt"><b>Item 9.01.</b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>Financial Statements and Exhibits.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">(d)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Exhibits.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company hereby files or furnishes, as applicable, the following
exhibits:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><a href="tm225039d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></a></td>
    <td style="font-size: 10pt; text-align: justify"><a href="tm225039d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Separation Agreement by and between Kiora Pharmaceuticals, Inc. and Stephen From, dated January 31, 2022</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><a href="tm225039d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></a></td>
    <td style="font-size: 10pt; text-align: justify"><a href="tm225039d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release of the Company, dated as of February 1, 2022</span></a></td></tr>

<tr>
    <td style="vertical-align: top; padding-top: 2pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="vertical-align: top; padding-top: 2pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-size: 10pt"><b>KIORA PHARMACEUTICALS, INC.</b></span></td>
    </tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    </tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 1pt; width: 62%">&#160;</td>
    <td style="padding-bottom: 1pt; width: 3%"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; padding: 0; width: 35%; text-indent: 0"><span style="font-size: 10pt">/s/ Brian M. Strem, Ph.D.</span></td>
    </tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding: 0; text-indent: 0"><span style="font-size: 10pt">Brian M. Strem, Ph.D.</span></td>
    </tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding: 0; text-indent: 0"><span style="font-size: 10pt">President and Chief Executive Officer</span></td>
    </tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    </tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: February 1, 2022</p></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6LboO/9ilQ0WcImOIt8VFKW7NSOt0j+Rb2m2IIRCSc74cIUZiSxtdIsNllaWQY1WXyiFkeENGc0XvSHb7GPzM8K6tY2Vcv/7AhDyDnpmNl8rfe2ejLRYxhPOJnE0iCaGMpws4HUTQ6QmZmy7QOK1KUKaAE1PNGp3idviQqzcZqto+6YxsNZkY5Dgc5A9EoYzgSI16ET8spGkiglFfgdgyPesu5mkdVbAusfJZdkD/HXwB4XRJHw== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>tm225039d1_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tm225039d1_ex10-1img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">January 31, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>BY EMAIL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stephen From</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Stephen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
letter agreement sets forth the terms of your separation from employment with Kiora Pharmaceuticals</FONT>, Inc. (the &ldquo;<U>Company</U>&rdquo;).
Your final date of employment with the Company is January 31, 2022 (the &ldquo;<U>Separation Date</U>&rdquo;). In connection with the
termination of your employment, the Company is offering certain benefits to which you are not otherwise entitled, in exchange for certain
obligations on your part. This letter is referred to as the &ldquo;<U>Agreement</U>.&rdquo; Reference is hereby made to the Fourth Amended
and Restated Employment Agreement between you and the Company, dated as of January 29, 2021 (the &ldquo;<U>Employment Agreement</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Earned
Compensation; Business Expenses</U>. As of January 31, 2022, you will receive a payment representing your final pay for all earned but
unpaid wages, including accrued but unused vacation time, earned through and including the Separation Date. All payments are subject to
applicable withholdings and deductions. You will also be reimbursed for any authorized reasonable business expenses that you may have
incurred, provided that you submit an expense report and supporting documentation in accordance with the Company&rsquo;s policies and
practices on, or immediately after, the Separation Date. You receive the earned compensation, reimbursement of business expenses and notice
described in this paragraph even if you do not sign this Agreement. Any unvested options and/or restricted stock that you hold as of the
Separation Date will be subject to acceleration pursuant to Section 9.2(e) of the Employment Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Continuation
of Health &amp; Dental Insurance</U>. Your regular coverage under the Company&rsquo;s health &amp; dental insurance will end on January
31, 2022. If you currently participate in the Company&rsquo;s group health &amp; dental plan, you have the option of extending that coverage
by electing continuation coverage pursuant to the Consolidated Omnibus Budget Reconciliation Act (&ldquo;COBRA&rdquo;). COBRA coverage
is generally available for eighteen (18) months from the Separation Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Instead of electing COBRA continuation coverage,
you have the option of selecting different health insurance coverage through the Health Insurance Marketplace under the Affordable Care
Act. The Health Insurance Marketplace will offer you a wide range of plan choices at different prices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You will be provided with appropriate notification
and election forms shortly after the Separation Date. Whether you choose COBRA continuation coverage or coverage through the Health Insurance
Marketplace, you will be responsible for paying your own premiums on a timely basis for such insurance coverage, provided that you will
be entitled to receive the COBRA Subsidy (as such term is defined in the Employment Agreement) as part of the Severance Benefits, subject
to Section 3 herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Your participation in all other Company benefit
plans will end on the Separation Date unless they continue by the terms of their respective governing plan documents. You will receive
the COBRA letter and the option to select different health and/or dental insurance coverage described in this paragraph even if you do
not sign this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severance
Benefits</U>. If you: (a) sign this Agreement on or before February 21, 2022; (b) do not revoke your acceptance of this Agreement within
the Revocation Period, as defined in paragraph 5, below; and (c) comply with all of the terms of this Agreement, then the Company will
provide you with the severance benefits as set forth in Section 9.2 of the Employment Agreement (collectively, the &ldquo;<U>Severance
Benefits</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If you:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;do
<U>not</U> sign this Agreement on or before February 21, 2022; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;sign
this Agreement on or before February 21, 2022 but <U>revoke</U> your acceptance of this Agreement within the Revocation Period, as defined
in paragraph 5, below; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;do
<U>not</U> comply with the terms of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">then you will not be entitled to, and the Company
will not be obligated to provide you with, any Severance Benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>General
Release, Waiver and Covenant Not to Sue</U>. Except as specifically set forth in this Agreement, and in consideration and exchange for
the Severance Benefits set forth above, and for other good and valuable consideration described herein, you, Stephen From, on behalf of
yourself, your heirs, next of kin, executors, administrators, agents, representatives, attorneys and assigns, knowingly and voluntarily
forever release and discharge Kiora Pharmaceuticals, Inc.; its past and present affiliates, subsidiaries, board of directors, parent companies,
investors, predecessors, successors and assigns; and its and their respective current and former partners, members, owners, shareholders,
trustees, officers, directors, employees, attorneys, fiduciaries, insurers, representatives and agents, both individually and in their
business capacities (collectively, the &ldquo;Releasees&rdquo;) of and from, and waive any rights in and to, all claims, complaints, demands,
contracts, grants, lawsuits, causes of action or expenses of any kind (including attorney&rsquo;s fees and costs), (collectively, &ldquo;Claims&rdquo;),
whether known or unknown, that you now have or ever had against the Releasees or any of them up to your signing this Agreement, including
but not limited to Claims related to or arising from your employment with the Company and/or the termination thereof; Claims arising under
common law; Claims for breach of contract and in tort; Claims for unpaid compensation, unpaid bonuses, equity or any employee benefits;
Claims for attorney&rsquo;s fees and costs; and Claims arising under federal, state or local labor law, employment laws and laws prohibiting
employment discrimination (based on age, gender, pregnancy, race, religion, color, national origin, ancestry, ethnicity, sexual orientation,
disability, genetic information, military or veteran status, gender identity and expression, and other protected classes), including but
not limited to: Title VII of the Civil Rights Act of 1964, the Equal Pay Act of 1963, the Fair Labor Standards Act of 1938, the Consolidated
Omnibus Budget Reconciliation Act of 1985, the Family and Medical Leave Act of 1993, the Employee Retirement Income Security Act of 1974,
the Age Discrimination in Employment Act, the Older Workers&rsquo; Benefit Protection Act of 1990, the Americans with Disabilities Act,
the Genetic Information Nondiscrimination Act, each as amended, and all related regulations, rules or orders, and similar federal, state
or local statutes, regulations, rules or ordinances, including but not limited to the Massachusetts Fair Employment Practices Act, the
Massachusetts Civil Rights Act, the Massachusetts Overtime Law, the Massachusetts Equal Rights Law, the Massachusetts Weekly Payment of
Wages Act, and the Massachusetts Earned Sick Time Law, each as amended. You further agree that you covenant not to sue the Releasees,
or any of them, for any Claims described above. For avoidance of doubt, this means that you have released the Releasees from liability
from any Claims, and, additionally, separately agree not to commence any legal action for any Claims. You acknowledge that if you bring
any legal action against the Releasees or any of them for any Claims, then you will be in breach of this Agreement. You understand that
the release contained herein is a GENERAL RELEASE and acknowledge that the Severance Benefits are sufficient consideration for your obligations
and release in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Acknowledgements</U>. You acknowledge that with your final paycheck, you have been paid any and all wages (including all base
compensation and, if applicable, any and all overtime, commissions which are due and payable as of the Separation Date, and bonuses) to
which you are or were entitled by virtue of your employment with the Company, and that you are unaware of any facts or circumstances indicating
that you may have an outstanding claim for unpaid wages, improper deductions from pay, or any violation of the Fair Labor Standards Act,
the Massachusetts Weekly Payment of Wages Act, the Massachusetts Overtime Law, or any other federal, state or local laws, regulations,
rules, ordinances or orders that are related to payment of wages. You acknowledge that you have not suffered an injury in the workplace
which has not been reported to the Company and are not aware of any facts or circumstances that would give rise to a claim that you suffered
a workplace injury. You acknowledge that you have received any leaves of absence and any reasonable accommodations to which you were entitled
under the Family and Medical Leave Act, the Americans with Disabilities Act, the Massachusetts Domestic Violence Leave Act, the Massachusetts
Earned Sick Time Law, the Massachusetts Small Necessities Leave Act, the Massachusetts Parental Leave Act, or any other laws, regulations,
rules or ordinances relating to medical leaves and accommodations and are not aware of any facts or circumstances that would give rise
to a claim that you were denied any rights under such laws, regulations, rules or ordinances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Protected Activity</U>. This release does not apply to: (i) your entitlement under ERISA to vested retirement or pension benefits;
(ii) enforcement of the terms of this Agreement; (iii) any claims to workers&rsquo; compensation benefits; (iv) any claims for unemployment
benefits; and (v) any claims that may not be released by applicable law. Also, nothing in this Agreement shall prohibit you from filing
a charge with the Equal Employment Opportunity Commission (&ldquo;<U>EEOC</U>&rdquo;) or with any other federal, state or local government
agency, including the National Labor Relations Board (&ldquo;<U>NLRB</U>&rdquo;) or from participating in an investigation or proceeding
of the EEOC or other federal, state or local government agency, including the NLRB. However, you waive the right to any personal monetary
recovery or other personal relief should the EEOC or any other federal, state or local government agency pursue any class or individual
charges in part or entirely on your behalf on the basis that any such claims have been fully and completely satisfied by the payments
you are receiving under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Time
to Consider Agreement; Revocation Period</U>. You acknowledge that you have been given at least twenty-one (21) days to review and consider
this Agreement and, therefore, you have until February 21, 2022 to sign this Agreement. You may sign it before February 21, 2022, but
if you do, then you acknowledge that you understand you had until February 21, 2022; that you voluntarily decided to sign it before February
21, 2022; and that you waive any time remaining before February 21, 2022. You acknowledge that the Company has advised you in writing
to consult with an attorney of your own choice about this Agreement, including specifically the General Release, Waiver and Covenant Not
to Sue set forth in paragraph 4, above, before signing it. If you choose to attempt to negotiate the terms of this Agreement, any such
negotiations shall not toll or extend the time to consider this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Once you sign this Agreement, you will still have
seven (7) additional days from the date you sign to revoke your acceptance (&ldquo;<U>Revocation Period</U>&rdquo;). If you decide to
revoke this Agreement after signing and returning it, you must notify the Company in writing. You can send the written notice by electronic
mail, facsimile or registered mail, but no matter how you send it, the Company must receive your written notice no later than 5 p.m. on
the seventh (7<SUP>th</SUP>) day after you sign this Agreement. Please address your written statement of revocation to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Kiora Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">ATTN: Brian Strem</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">1371 East 2100 South, Suite 200</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Salt Lake City, UT 84105</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">bstrem@kiorapharma.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless you revoke your acceptance within seven
(7) days of signing this Agreement, the eighth day after you sign this Agreement shall be deemed the &ldquo;Effective Date&rdquo; of this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Nondisparagement;
Relationship to the Company</U>. You agree not to make or provide any derogatory, defamatory or negative statements or information to
anyone about the Company and/or any of the Releasees or any of its or their respective services, products, directors, officers or employees,
unless compelled to do so by law, or by an order of a court or other forum of competent jurisdiction, in which case you will notify the
Company promptly to allow the Company sufficient time to intervene to stop you from being required to make such statements or information.
After the Separation Date, you must refrain from representing to others or giving others the impression, whether directly or indirectly,
that you are in any way an employee, agent or representative of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Employee
Proprietary Information, Inventions, Non-Competition and Non-Solicitation Agreement</U>. The terms of your existing Employee Proprietary
Information, Inventions, Non-Competition and Non-Solicitation Agreement remain in full force and effect, except as otherwise provided
in Section 3 of this Agreement and as modified by Section 10 of the Employment Agreement. If you breach paragraph 7 of this Agreement
or any surviving provision of the Employee Proprietary Information, Inventions, Non-Competition and Non-Solicitation Agreement, the Company&rsquo;s
obligation to provide you with any Severance Benefits will immediately terminate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Cooperation;
Return of Property</U>. You agree to cooperate fully in the defense or prosecution of any claims or actions now in existence or which
may be brought or threatened in the future against or on behalf of the Company about which you have knowledge or were involved by virtue
of your employment with the Company, and in any claim or action brought by the Company against any other entity about which you have knowledge
or were involved by virtue of your employment with the Company. On or before the Separation Date, you agree to return all of the Company&rsquo;s
property, including your identification badge and any and all keys, passwords, external hard drives, laptops, phones, software, spreadsheets
and any other property and/or information that you may have received, created, or accessed as an employee of the Company, including but
not limited to any documents or data stored on any Company device or on any personal device. You agree not to retain, and represent that
you have returned, any copies of any property, documents, spreadsheets or information, including but not limited to paper documents or
items stored in any electronic format, which was made or compiled by you, or made available to you, relating to the Company, its clients
or any of them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Nonadmission</U>.
This Agreement shall not be construed in any way to be an admission by the Company, and the Company specifically denies, that it has engaged
in any wrongful or unlawful act with respect to you, your employment or the termination of your employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Breach</U>.
You agree that if you breach or threaten to breach the provisions of sections 4, 6, or 8 of this Agreement, the Company will suffer irreparable
harm for which money damages may not be adequate. Therefore, you agree that the Company shall be entitled to equitable relief, including
a preliminary and permanent injunction, without the need to post a bond of greater than $100 or to provide any other security, to stop
or prevent the harm to the Company, and to payment by you of all costs and attorneys&rsquo; fees incurred by the Company in enforcing
the provisions of this Agreement. The Company will also be entitled to all other remedies available to it by law. Notwithstanding the
foregoing, under no circumstances shall your aggregate liability for any breach or threatened breach of sections 4, 6 or 8 of this Agreement,
including costs and expenses payable by you in connection with enforcement thereof, exceed the value of the Severance Benefits actually
received by you hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous</U>.
This Agreement constitutes the entire agreement between you and the Company and supersedes all other agreements, whether written or oral,
with respect to your employment, its termination and all related matters, except as provided in section 7 of the Agreement. This Agreement
may only be modified or amended by a written document signed by both parties. If any part, term or provision of this Agreement is determined
to be illegal, invalid or unenforceable, that term or provision will be stricken and the remaining parts, terms or provisions will remain
in full force and effect. This Agreement will be governed by the laws of the Commonwealth of Massachusetts without regard to conflict
of law principles. The parties agree to the exclusive jurisdiction of the state courts located in Middlesex County, Massachusetts and
the federal courts located in Suffolk County, Massachusetts, and waive any defenses to personal or subject matter jurisdiction of such
courts, to any disputes arising from or related to this Agreement or the enforcement of any of its terms. This Agreement shall be binding
upon and inure to the benefit of the Company and its respective successors and assigns. This Agreement may be executed in duplicate counterparts,
each of which shall be treated as an original, and signatures submitted in electronic format shall be considered originals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations</U>.
You represent and agree that: (a) you have carefully read and understand this Agreement and, in particular, the General Release, Waiver
and Covenant Not to Sue contained in paragraph 4 above, and fully understand the final and binding effect of same; (b) you were advised
to consult legal counsel before signing this Agreement and have had the opportunity to do so; (c) you are not entitled to the consideration
set forth in this Agreement, but for your signing this Agreement and not revoking it within the permitted timeframes; (d) you are signing
this Agreement knowingly and voluntarily and for reasons of your own; and (e) the Company has not made any representations inconsistent
with the terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Please indicate your agreement to the terms of
this Agreement by signing and returning to Brian Strem a copy of this letter no later than 5:00PM on February 21, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>Kiora
    Pharmaceuticals, Inc.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt"><B>Stephen
                                            From</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">/s/
    Brian Strem</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: left"><FONT STYLE="font-size: 10pt">/s/
                                            Stephen From</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">By: Brian Strem</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Date:
                                            1/31/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Its: President and Chief Executive
    Officer</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Date: 1/31/2022</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ACKNOWLEDGEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(To
be signed only if you sign before February 21, 2022</FONT>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Stephen From, acknowledge that I was informed
and understand that I have been given twenty-one (21) days to consider signing this Agreement. I have been advised in writing of my rights
to consult with an attorney of my choice and have done so or chosen not to do so. If I sign this Agreement prior to February 21, 2022,
I acknowledge and agree by signing below that I have voluntarily decided to waive the remainder of the 21 days I was given to review this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Acknowledged and Agreed,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">/s/
                                            Stephen From</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: left">1/31/2022</TD>
    </TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Stephen From</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Date</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>tm225039d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt"><B>Exhibit 99.1&nbsp;</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt"><B><IMG SRC="tm225039d1_ex99-1img001.jpg" ALT="" STYLE="width: 213px; height: 74px"></B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Kiora Pharmaceuticals
Appoints Erin Parsons to its Board of Directors; Stephen From to Retire from Board</B></FONT><B> </B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">SALT LAKE CITY, UT, Feb 1, 2022 &ndash; Kiora
Pharmaceuticals, Inc. (NASDAQ: KPRX), (&ldquo;Kiora&rdquo; or the &ldquo;Company&rdquo;) announced today the appointment of Erin <FONT STYLE="background-color: white">Parsons
as a new independent Director of its Board of Directors (the &ldquo;Board&rdquo;). Separately, the Executive Chairman, Stephen From,
has informed Kiora of his voluntary resignation from the Board. These changes are effective immediately.</FONT>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">&ldquo;I am pleased to welcome
Erin Parsons to our Board of Directors,&rdquo; said Brian M. Strem, Ph.D, President and CEO of Kiora. &ldquo;Erin brings extensive commercial
and strategic expertise in eyecare, a critical and complementary perspective as we continue to dedicate efforts to develop therapeutics
for eventual commercial successes.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="background-color: white">&ldquo;This
is an exciting time to join Kiora&rsquo;s Board,&rdquo; said Erin Parsons. &ldquo;Their pipeline includes KIO-301, a photo-switching
small molecule drug that has the potential to restore vision in blindness caused by retinal degeneration.&nbsp;This could be game-changing
to patients suffering from a rare form of blindness called Retinitis Pigmentosa. Additionally, KIO-101, a proven next-generation anti-inflammatory
may provide a novel approach to addressing ocular surface disease in rheumatoid arthritis patients. I look forward to working with the
entire Board and leadership team to further advance these promising therapeutics.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">Erin Parsons&rsquo;
extensive knowledge, experience, and network in the eyecare industry bring to the Company a broad understanding of the unmet needs in
ophthalmic diseases in the front and back of the eye. During her career, she participated in the commercialization of XIIDRA&reg;, OXERVATE&reg;,
LUCENTIS&reg;, BEOVU&reg;, DUREZOL&reg;, ZIRGAN&reg;, among others. In 2010 she founded Parsons Medical Communications where she currently
serves as President. This leading agency provides scientific and strategic consulting to small and large companies in the ophthalmic
space. Click <U>here</U> to read her full bio. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="background-color: white">Stephen
From served as Kiora&rsquo;s Executive Chairman since early 2021, and previously served as Kiora&rsquo;s (under the former name of EyeGate
Pharmaceuticals, Inc.) President, CEO and Director since 2005. Kiora&rsquo;s Board accepted Stephen From&rsquo;s voluntary resignation
to pursue other activities. Paul Chaney, Kiora&rsquo;s current Lead Independent Director, will be assuming the role of Chairman of the
Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="background-color: white">&ldquo;On
behalf of the Company and all our stakeholders, I would like to thank Stephen From for his hard work, dedication and contributions over
the years,&rdquo; added Dr. Strem. &ldquo;I&rsquo;m confident of his future endeavors, and I&rsquo;m deeply appreciative of his focus
on making Kiora a successful organization with a first-in-class therapeutic pipeline.&rdquo; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[The registered trademarks mentioned above are the property of: XIIDRA,
DUREZOL&reg; and BEOVU&reg; (Novartis), OXERVATE&reg; (Dompe), LUCENTIS&reg; (Genentech/Roche) and ZIRGAN&reg; (Bausch + Lomb)].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm225039d1_ex99-1img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>About Kiora</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Kiora is a clinical-stage biotechnology company
developing and commercializing products for treating ophthalmic diseases. KIO-301 is a molecular photoswitch that has the potential to
restore light perception in patients with inherited and/or age-related retinal degeneration. KIO-101 is a next-generation, non-steroidal,
immuno-modulatory and small molecule inhibitor of Dihydroorotate Dehydrogenase (&ldquo;DHODH&rdquo;) with best-in-class picomolar potency
and a validated immune modulating mechanism (blocks T cell proliferation and proinflammatory cytokine release) designed to overcome the
off-target side effects and safety issues associated with other DHODH inhibitors. In addition, Kiora is developing KIO-201, a modified
form of the natural polymer hyaluronic acid, designed to accelerate corneal wound healing. For more information, please visit&nbsp;<U>www.kiorapharma.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Some of the statements in this press release
are &ldquo;forward-looking&rdquo; and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of
1995. These &ldquo;forward-looking&rdquo; statements include statements relating to, among other things, the development and commercialization
efforts and other regulatory or marketing approval efforts pertaining to Kiora&rsquo;s products, including KIO-101, KIO-201 and KIO-301,
as well as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all. These statements
involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including,
among other things, market and other conditions and certain risk factors described under the heading &ldquo;Risk Factors&rdquo; contained
in Kiora&rsquo;s Annual Report on Form 10-K filed with the SEC on March 25, 2021 or described in Kiora&rsquo;s other public filings. Kiora&rsquo;s
results may also be affected by factors of which Kiora is not currently aware. The forward-looking statements in this press release speak
only as of the date of this press release. Kiora expressly disclaims any obligation or undertaking to release publicly any updates or
revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions, or
circumstances on which any such statement is based, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Francina Agosti, Ph.D</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(617) 546-0742</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">fagosti@reportablenews.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>kprx-20220131.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.11a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaeJSbOdzZR+OYkxtmB8bek6nywqWzfRIiSmcjCWMWoF -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:KPRX="http://eyegatepharma.com/20220131" elementFormDefault="qualified" targetNamespace="http://eyegatepharma.com/20220131">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://eyegatepharma.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="kprx-20220131_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="kprx-20220131_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>kprx-20220131_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.11a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>kprx-20220131_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.11a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://eyegatepharma.com/role/Cover" xlink:href="kprx-20220131.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://eyegatepharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm225039d1_ex10-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm225039d1_ex10-1img001.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !3 /<# 2(  A$! Q$!_\0
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MGQCKOCCPS:^$[&*VU2SU:^TW1;'Q9XNL=(N=,N+CPM'=>)/"=EK_ ,^_M_\
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MSK_@DM^T9XM_:U_X)]?LS_M ^/Y4NO'?C'P1J6A>--2$"V[Z]XK^&OC/Q/\
M#+7/$LT,4K6T=]X@N_"!U+5/L4-I8&]F:'3;#3-+MK'3K;^4_P#X.@_CEIGQ
MY_:O_9B_9+^&-N?'7Q!^"NB>+E\7:9X4L[_6[]OB'\>]1\ 6WAWX<S1::+VZ
MNO%[>'?AGX<UZ30]/TWS8X?&-E:6%[K=W:W\5I_6C_P2_P#V9=9_8U_85_9P
M_9G\3&-O%_PZ\#7=[XZACN[6]CTGQSX^\2ZS\1?&&A6=[8F6QU;3M$\6>*_$
M.@V&L6-S/;ZC:Z)%>,XGN988 #[]KFO&'B#0?"7AK6?%WBF_M=*\,>$M-O\
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MU"Y?4;*4(=-NX[G5M.UZSU+0-:UW3=1_SJ-3T_\ :[_X-^_^"AMALNIM8M]
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M=J.F_!WP':W=CJ5K,(KFUN-/O(9([FWFBC=9[.:.=&B\R%_QO_X*V?\ !O\
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M._M,_ B]TB]L+:RUFTU;4?$<_BZZ\5KJ6ESVESIZ^'[W^T/)?@'X^\5? /\
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MTA::21VT:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
'"BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tm225039d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm225039d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !* -0# 2(  A$! Q$!_\0
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M?B*Y$[V_[>O[+.BPM.J,EO9Z)+\#O#_AZS"ME$EC71M-E23@%+=94"%Y'?\
MT/EC*Y_>2'=C<6;>"-V678^] )!\K[57Y>%*D JN(I3RW).&LIP_)A8/+Y8Z
MK4A%?[;.M*'LI59)1YI4(WC%R<W'GM9))BRN7UO'9W.L_:*AF<XTHPO-Q3BE
M)22^!/DC9/>SZ*Q T*Q!0JM)L;*-*WG.JG&Y%EG$DFTD9.69N>& "@?S/_\
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MOPE^"G[/?[-.G^)?$WQ'^ GQ%^/.NVO[0WQ,\7?LXZMX"M?AE\5_"7P=\3>
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M1?Q>M/BAXG^&/P!^ &E_'+4OA=X9\)>*?BP/$/Q>L?A/?6<?BV;7KOPIX?\
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?-$F$!VJ=N[:%#,Q&:*N44K/^:?\ X$Q\D/Y8_<C_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139836013209256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan. 31,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">KIORA PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001372514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0443284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1371 East 2100 South<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Salt Lake City<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">788-9043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">KPRX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>tm225039d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="kprx-20220131.xsd" xlink:type="simple"/>
    <context id="From2022-01-31to2022-01-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <startDate>2022-01-31</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-01-31to2022-01-31">0001372514</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-01-31to2022-01-31">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2022-01-31to2022-01-31">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-01-31to2022-01-31">2022-01-31</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-01-31to2022-01-31">KIORA PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-01-31to2022-01-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-01-31to2022-01-31">001-36672</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-01-31to2022-01-31">98-0443284</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-01-31to2022-01-31">1371 East 2100 South</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-01-31to2022-01-31">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-01-31to2022-01-31">Salt Lake City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-01-31to2022-01-31">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-01-31to2022-01-31">84105</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressPostalZipCode contextRef="From2022-01-31to2022-01-31">84105</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-01-31to2022-01-31">781</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-01-31to2022-01-31">788-9043</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-01-31to2022-01-31">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-01-31to2022-01-31">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-01-31to2022-01-31">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-01-31to2022-01-31">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2022-01-31to2022-01-31">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-01-31to2022-01-31">KPRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-01-31to2022-01-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-01-31to2022-01-31">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M,AF**I9P6B#BR2!M:59]L$].M.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04
M" "L-4%499!YDAD!  #/ P  $P   %M#;VYT96YT7U1Y<&5S72YX;6RMDTU.
MPS 0A:\295LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2%85-K'C>O,^>
MEZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-X
MJBA[E.O5,[1R;ZEXZ7D;3?!-F<!B63R-PLQJ2AFC-4H2U\7!ZQ^4ZD2HN7/0
M8&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U .EK >MKBRAE#VQH%.JB]
MXY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D(TAD
MIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_
MYHOA/UY_ 5!+ 0(4 Q0    ( *PU050'04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ K#5!5'NM4JWN
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ K#5!5)E<G",0!@  G"<  !,              ( !S $  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "L-4%4SQC#CTT$  #4$
M&               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ K#5!5)^@&_"Q @  X@P   T              ( !D P  'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " "L-4%4EXJ[',     3 @  "P
M        @ %L#P  7W)E;',O+G)E;'-02P$"% ,4    " "L-4%4JL0B%C,!
M   B @  #P              @ %5$   >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ K#5!5"0>FZ*M    ^ $  !H              ( !M1$  'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ K#5!5&60>9(9 0
MSP,  !,              ( !FA(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2      D "0 ^ @  Y!,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>122</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm225039d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyegatepharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm225039d1_8k.htm">tm225039d1_8k.htm</File>
    <File>kprx-20220131.xsd</File>
    <File>kprx-20220131_lab.xml</File>
    <File>kprx-20220131_pre.xml</File>
    <File>tm225039d1_ex10-1.htm</File>
    <File>tm225039d1_ex99-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm225039d1_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "tm225039d1_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "kprx-20220131_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "kprx-20220131_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "kprx-20220131.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 122,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "KPRX",
   "nsuri": "http://eyegatepharma.com/20220131",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm225039d1_8k.htm",
      "contextRef": "From2022-01-31to2022-01-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://eyegatepharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm225039d1_8k.htm",
      "contextRef": "From2022-01-31to2022-01-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001104659-22-010000-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-22-010000-xbrl.zip
M4$L#!!0    ( *PU053-!4:5/P,   0,   1    :W!R>"TR,#(R,#$S,2YX
M<V2U5DUSVC 0/;<S_0^JKQUA&YHT(9!,2B8=6M)DH EI+AUA+Z!B2XXD!\BO
MK^0/(& HD-8G>?>]M[O2KNS:V20,T!,(23FK6V[)L1 PC_N4#>K6;0>?=QK-
MIH7.3M^]1?JIO<<875((_"JZX!YNLCX_0=])"%7T!1@(HK@X07<DB(V%7](
M!&KP, I @7:DD:KHH.2Z!&&\A>X=,)^+VW9SICM4*I)5VQZ/QR7&G\B8BY$L
M>3S<3K"CB(KE3,V9.-FS'?V*2F]&_D#.#\:?)FUZ/P!V%+=(Y<'K$OC:Z5W[
MSP_M#]<_1Q,5?C[JP>B03<>/W>=^NTD[H?>[T;WJ\LLT9$UZ0P@)TH?!9-TR
M]67EC2LE+@9VV7%<^_ZJU4EP5@JL3@+*1D5P]_CXV$Z\.70%.>F)()>NV,;=
M(Q)FRMI+-^ IDXHP[P7>5S/"(OC 3ITOH+00>IA":0[U80DGP2L-^).M'1I?
M=A\_YM!8X@$AT0S>)[*7R&:.!(X=%U?<G"*%6H5K8S$4JVD$LI"0N@IHWV[:
M]S,&3&% %$1#(D)BFM40RHYKX!! "$Q=<A%>0)_$@<[L,28![5/P+:2(&( R
MW2<CXL$VDGD?$\:X;G<]<YG%V**(ZG[6AC<U<_!5P0/XH6M 9J$';4, @[ ;
M7-\8%J)^W4J71DH+)V(^]"FC2<1LK%R$S1#%ID2]3"@U>QF\(!%+\*_9:;*.
M!$C-2TIH:4-&S"!K2!X)O#C8C3-/I9"2&?*MFF]>/CIMZ*-DY*JF'>J6I.;2
MLS+;4$"_;HTB,<'Y&?W2I95TH^00([UAY)*=7]Z-+' N082WHK)R)6@1'H%0
M5/?LPMRGJ5-EZ#<+89")(RUD_XN2 ]+;M61-@> _UMHR^HM%9E-BS\<D>U\>
MI9HNEPN%V,I@;KHPTZN^Q;U$:@/%O.&<AXT)NV5]NY0FTI]GNDL2\QW8+8F<
MMT<2:Z_MH@SD>H)9XG2Y;>B-GX"-X0N9-@1*YA8\U]HGG=4/QBOR2<3V2.C%
M8?M*V$;(2#M&I[PAJ;\QDW>Y5XMX/&9*3),*MVR214K^DFS'SB>S_/'?[E!R
M5GH@YG_@%<U1_#NQ;R+K6Z-FIYIZ^0=02P,$%     @ K#5!5/FN/4__"@
M;(<  !4   !K<')X+3(P,C(P,3,Q7VQA8BYX;6S-G5]3Z[@9QN\[T^^@IC?M
MS DY@;8SL(?=X>3 3F99H"3G;-N=SHYBB^#!D:CL0/+M*UF68\MZ;4.GDKB
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MF*J   &L 824:K28SWSW*DN\F\<"V.0A4<^7]Y "ZMT"TV.[R0T@#@B?;H<
M12((-:-\PS2G$>//K/:XQ(QM16.XG[$8'K'T1+D%:U 1FGAUA@0$V1"? &J-
MT _JF1;$Y-R@(@,D<_!&W44<BX.5E7^N$TJFX#&P:MT2UF&WR95%&!!-L#N
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M>R_WY@7IUUBCWZA B-XKDO*5(7'L%FJ45WB9,.TA'[+'LB?=^.D72D#_ULQ
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M$J7/,+=*[5 @.\Q=B/2O5=C</8. !-)A6;^U17P"7ZFT'C#)$=9LC3$#/<?
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MPY+JX22QOVQ0\QLLD\VXG'49.4'8"]D8 W^.MSF#65M(]X4(#9D!\;,KC%Z
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M]X26*KTFUD/#9&/AAC3)!NV-"+;,38@[19F%5PW$0066W3!7G]FN$$+?)R3
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M73WK:R):&G3,L/;W\?V"?0!^/BP\S/J$TIK27R*6+ECZVNFUUE5)1:G52=8
M2=O-,SJ;$%U0LP8FM((7BI<P(5CJ&4SX@I39TNE]B]6^WT8:)JD(R%&6D6YZ
M _^#0GDG)M;M>$S(LSM8[2[&=,B,$SNDV-<F1S8AU2O7B:D2-GD#-AEH!_V@
M,.RB((TM7,12%ZG=F)$D;V-K0[3Z.J[L]*+J%R::JE72%WETN !@%D=DR*=.
M>5VL\:U!R80ZX=3""XWU8&7[UA'0<TIFM^,ID\_9Z#;I$V&P'YUO0M0J9[Y
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MT+K6U<_9!":QS<L,7#HD<RZ6F00KTH,*WFN2I;KDB@J2?AA_VJRC?@@>7CU
MPBDXIK_@^\#=+EI*(;2CPX(991/W(=V7Z:2P"5=\RG J<[A&7*&D"R**#B+Y
MHZ+KT*C,EBV)-^KWH'(Q)0[H:':UX$05 R,DCZ%<(9J4 HCF!*V@\;P_JFO@
M;\C7[^!$>/X/=B(\_^9$^!L1\<K;E_=+UL $K D>6*>A+ZCG$J]N\ JT;7]H
MF2E*<"!@B0M/:+SI,^*]:G5[:TU%P;20]/5K0YL5)B7SS^66L3> 8YV@$L_)
M4!&3C!=DF\$YOJCV\J,UHOFF*9>FJ_4D(%:G,WL.X(6[]IR]LK9HV=)VFI>\
M= Q2MT-)]<^6K:W;:89H^12:F#X;UJ2G!8:#U,LVMP1[OJT*@S:(K@T4(\Q!
M<FF2V^@I.^C3HHI+IX?4,=W:(X(HO!1A(<Y0E<L#YNU4'Q??RA&!N25U2*H/
M*MW.#VK2 %_T7%*/!80+WINRJ:"4 A%H"&5).B0K"ZD>9B77H]R8S>S$;K?C
M7F#-291"B63 497;$DH9#!BR #2/+ED?B_^<@ONS9V+^#'JE,_0T_2_%Y@67
M#ZR^6O-"1,(BZGI-[J'1C)HM2WCWE-:%S,OKF&&/-Y\]=OW9(6?9#U<;.?*1
ML$E9Y9:89$<);5[JEZ:MD]2<'#EV(8+WCAQPAVC#EI<K5U*;9ZD)NQTZQZ1;
MDCG/,5C6+\GD-F21P2LE=R6.2E^XU&.4301"FE.CVKT]>(6N6(B!-C,]C0.'
M&8B2%OE2C=>3=9790@%&$!VQU5>[%[^<O2U'NQOXRWS< F@)QM?5F<TPBR+D
M);3G9M79F8QY@R^R4+^RP\#_;RU-<;TAH^ZQEK!W>?F!=,K<$'HO2A(4CS7Q
MUO-76^H(6L#VUN:FNB"),**!*D,G>GMS\[&6<1&0S#H)KI#(@FR;7R[5#R^V
M-E\^-*$YK6\+*E^_ *3_^PKH'S/VU\,';#CU6#S]%RE<FW)3C85\UV;K,Z/H
M=L#*F7^CE'Q)UAQWY8")/KJ=BUBYVH=GDBY$?N+CT6!@LSX1T7$-@:S([G8^
M@WA]+*A_?S]-7M* 6 42]9T3L$4Q&9GQ3$3"T^3][(L$!T1\-ISA#ME!JDHV
M1 XR.A_I09#P9SQ%N@\GMC:,W#HWFN0D[FF33J'Y.V5P+K&QR;U8F)-A9-2Y
M+-]"Y]>&4XMHM0AQM1-U7?8N:V%UTBX"$TS,[&&,;1EM1)IW!A$<V\@4'(*I
M!)78M4Z/5^*:L=Z?+*\22:*D84K0Z.]5;HK(A)*W!]'/H9$0TL^O.[!*@O0^
M8M\4*3GCDAVS"&^2&/=AY.5U. 72P."G@\9?"C*4&^]C7^.LY4C*M!VT&*/L
M(5J*I'4Z)LMJJCT%APRP'#W!>*)6@R4DM0(L//!0G$?V H9$)-+E)+ID74%4
M/'7.,/G6\^*=\$6Q1W%*5@ZCPV'1IL*+3N0G6->IB@*[)Z)1O[IG:RT+I6[G
MC&OKV=WI)PQ"[X ^)[$;8AO/N M7:>KR"5R[X$9,MGE3N^L:]^EHM]73GT@U
M!=KK_$IO\F[G@6:W]BW( MY-Q2$'27ME*8#R"5=%TO2F<Z7T7"G65*S/EYQ)
M@8%*LL@X%ZE[?&OSQDY)SIJP66&-'?IJ?IHZ3:^HB'_Q6>$5%EX4?A$4'PJ%
M+</ )6+[[?D653@M*7 2IN8WY7()ZD^EI<Y=W+\O_L'NWQ??W+]?BC1_N&]C
M,V0#\0EGU1!.#/";,\X2*N<T0O94R2O:!I-L"@PI@=SV3_3$ @5KEG=YL58P
M.9MUA.H;;@L*]P5G&N>B','-@2X:Q#?1>Z44-8^(@AYK.I4,*EJJKE-WH8-Y
M575MA9)5S"8GA?W$C:O3I7.9]#J+K_UT+HY,WBV?R^HDDC=1[[+>0K_M G*K
M;@*'KECCQJ6RD%BRUKNDGJVK4[\D>ZEB5Z-:G%I^)X<Y"3&VA.([<'D=4H#B
M>O>H?@!8N^PAE[1WQ75RXZ H)L3G4#CTB?@6/'TC1)NC7&H9XV!,1Q]/CLAF
M0'5>-BB1X4*?2-4+HF*D=6D3F!N@NK4YDZ)E@LQET+G$IYX*F=@B2=KA2D-I
M[.IIFS/PN*5P1BPFUZ,%PT9!&4!+SVUM43JMB2/2,& L1;?"U')G@8%&> J,
MK>VIE5^;9.XE=@&94O.!5C-CTY3A-5BL5]D&[8QQ<$OAQCC@%$-OPZ1FD9E1
MN"W;X]+X-I4,W;.T/X'&A5:]W(PI&1N;9LG%M'2-[S6M_:08K]?*EVICAQ81
MQD9BVNW$_B>BDKR^MU\ E<1L?S&/[W8N%WE7;$X,HA,E][SUC*^26\PBV.-&
MFN%S<]7S[= .)Y05MB#3E!QBTNF01+%HY3P/4<>0Y(Q4<)(ACL\H3V3>9NW^
M&O^S#'!!?>0\FWPB!+"U>0L%$-;WV1*Q^/:$>JM&1DI8&IG+>):KG!OBS!)Q
MY&DKSE_TU/=\-']8TN>GU>+'9J@JD^<L@.@0=SMPA7+REO  ).40D00)9P][
M"5IT]O^HN+/;93L [.VF173.3^CW2.,*568>DM?3JM@-4-\9<^E<+L**^!GA
M!32%+-K4^G- A,Y]E6K+^S((=N2/<X7[D(%H(RC_!5\W0)NU?&DBK0I;:=AS
M#ASF5..<PRP\!0-HEK5)L7:=SRQ,DODZJK=10"O2UI6ENV0Z+K)U'9UG%10H
M9IR[9[/-9]$^&\^YG,6O:T#M@[QIE8;,P8C[.?LLW)36V;:.8"Y@6Z>SLVL,
MB!YF]+5GDY#2;":C53 M;N@AK0Z].9H2M+J$:Y[& 8&Z=JM%T\M(FKMA6PG8
M0+DN;W=5!A8=9KX3OY\;:8NVQ5-A/=EH,%&K&8O*N\*2&P1PSIID;-O),!@#
MZ*EPMMO:R!-G>V^*4,<Q'=&L*A8+-)9AABM3)<[ Z73>3T3<T-U?V2[F&JW4
M0;<U*=>O%XT;TT4R.?<YB-&-8%Y:M7]R@7]-P1-3LV6Y$LXM?%]6W0R20RQ"
M6:\<P;3.9MO1!$Z:I3&;6+57"R=#ZDW9RUUOP>EP'("1F]RB@G,\435Q;!5(
M^MZ3KI(N4-"XKEIHX*:3LE7(>5$BB&6@(!-,F.C>1"+N[1&16A]AZW,3U%W.
MT27]2J<UYIJL%ZRMZ#G?9.ZS,MLH,>'?HECF0)P%83VG9'4VW)/["C2& 0FP
MB;11I&OM"@$G.,"B\LCF?PQB@PZ:]# -A.;$:6C&,8!\R3F9#/'&.&,:_D0\
MJ("3VP\TN#5($BH'*0I.1"V%6MZ;**)Q]2=:995"XK17QUWVV<B6=-8%0UR0
M_,[BJ\4#S'86L:X!3NZJC1GN<RJ=Z6VNPNP6))5&YN[55I0IQGR$6]TRV.E?
MU_;,]B'+[7EO):-[<22FC#DLUVI#WZ2B%E1C>S)-"M^#Q8%-+I_S.MA>-'YL
M:F';FKF)K?M#FOX(N*.*\] %FW#M"4UW.TYFB<I4+[D4"]8:K=*! L=+ZO>'
MQ&1H X7]T08[QYPQU@SGDI.84<A83Z6-U5U<N2__P:[<E]]<N5],[[GM1RHX
MGZT)==(A]4R[Q@\D_:6<:22=96NO4!B0!<5^7#A[^-E6GX+YK%M;D6!"_+!%
M[Z8$3?''+6CNYG4[:"=HMIJN\:I:B]&VN)@+=(4K6QG-\H)(5_K?UC5K-F.U
ME:(JK1_ 1PL=SV:"+@C^,9B0OUMRR^2F.L>E".QPZUO_)[!\JP=OM7HO(+7Q
MAO9U<*?5W1EN6%;=X%=R#OW6F#!6A:TC.6"0$UQ0)A4UB[3CSJ55+^T.IUP;
M/*G[;&*\V22U555Z;2YA&&L45QU7C+9(%;8GP +O?VDUY!NR:Y^(N#ESS34B
M$>?65G7PM_3B8#"'G_YT2=(IO>AE\7%JRGA:0]'V_9Y)YWRSN7GV'D[F^7SP
M1P;VY=[^R9$Z.#HY.=L[/#S^\-./*YLK_/WB;._ ?7="1<0HVL %XX+DBONT
M@Q_^*$=8Y>:_5U@V[%Z>N]>XS#P,8K<6D3<K3H1<'MY_I_[68CT@639&KG(Z
M;(39'83ROB2"RCJ69(/N-]+V\O#MGUKLGUB:PU(S\P,"Z_Z3/\JTA [;K-/^
MQ/(=_\EOAL[@:>/R_&LAPP<"]S<J^[/3_A5:N=FRD&KRNVW$<M 7K__]0'2U
M46S(<EM)YG\1W([/__MS$=QM /46\(5H\W%0?F?LWO5?^R>6YS#P91CF;;O<
MG[YY0/+]Q@_GIT7NR9O[4=+6QO.M#?E!]2\N<6_;WG%9O%%G9/UP4HS4+8[0
M3."(?7S\*SU8S*EDI\^ _Z_3RX-2@3\8MU-X9&'W4.>,:6X)&3UMH&^PO<6F
MU]=N3]_%??O]/]A]^_TW]^TCDZ8@G W)O8/_?#C][>3H\*>C]T<?+L4\_+R3
M/EB_J=7+C']7T,9].6!L4X2X%F]9*P%+5FN?>:./PUV.9W^Y8ZY%PC&G*DIF
M)/?;F_6?\S.S+3"6=;ZHFP L]ONNMX9RW1B:>G+X^Q+7G>W6M@STI&O(X+S<
M$594\(\1T*U""L%K/S<'^X\7EF*.<R-I3?-],[J=XQ;8FFB$Y\SD7V=J06M)
M*PRODQ-'[6TI'BYL;PD<!246T'4WD<]6^/E%Q9_7H%5B-[S!J/<T=O?W] ]_
M#<Z6OVJ.?_/*_+V],I[5\N6=)VTB^N84>4BGR"T&W!/A[S<8;Z^\GZP_0;^0
M?YH%]^K>%MR3,J<^URQS V[LGQY^Q)':^/GR_<G;_P=02P,$%     @ K#5!
M5(!S5LSI#   5BL  !4   !T;3(R-3 S.60Q7V5X.3DM,2YH=&WE6FUSVS82
M_JX9_8<]?\C8<Y)LN4DZ?JGG;,M.-'%BGZUTVM[<W$ D)"(F"18 K:B__IX%
M0+VX3IIVXC37RX<X)@GL8E^>?7:1PY>CUQ='[=;AR[/C 7X2_SD<#4<79T>'
MV^$GWF['UX<GEX,?Z6;TX\79=QL37;I]ZN]4CD:JD);>R!E=ZT*4G?"@0S?2
MJ,D&%F+IU;UU3W]KW0$5PDQ5N4\L8N> G'SONB)74SQ*9.FDV3@Z/+]\,UK=
MN6O5+S*HA;<G1T_*L:T.#K=/<![^%C^N'D,AHZ:9^P1]SMYG:JP<[>WU^E^;
M;E]*GUQ./D6=P^'K%W1S??K=ABMV=Y_M?+.7]O\CW^_M=?NJF.[L]'OOJND&
M'5^,OMO8:#::J=1E^[3;_Z9Z?T"9Y*/OT[=/J_?8\]%/]M6%Y2<K]$II(^@J
M$Z80B:R=2D1NVZWCJM*J=);.C"KI2ABK2TM.D\*S$RU,2GI" V5DXK2Q!W3C
M9)7)DLZ-+OB[:^GPDB;\J_]^]<PG1Q1^_1//WGCBXU[X391;%_VNMDY-YO?4
MVSBZ0;#2Q?&K,SH=CG[LT-M1A\[EF/H=VMW9W:4G92IL=D#>&^W6/7=T:%@F
M/=I\<WPS./[G/KVZNOYAJT.;3_+TYUH?^$5/C/\W:4,NDQ1?G>JB$N4\OMPB
M49:Z+A.9PD6IF/M/17!U :NQ3[W#UTPW%LGMU&!=VDUTKLT^S3+EY,91#(MV
M2U@25,) JDQE)?$7]FJ"@S=].&IH<T55_[I1M ?C5L(()_-YQVMY]EXF,,>=
MI--,*./]L!ISG78K@QJJG&A3X'PAKB$M4Y;N=%Z73I@Y&6GA*.&4+D-L\MY>
M=(]&F;22DDR44_A;('KE9 )-6:@JL*GR^O1BS- ?#9A[L=$$XOT(?#"N_K"4
M3_-H],601$%5+H7UD4(SF2>ZD.W6?330M7G KYTF&*U0*9T8)4IZ#9<Z(XL.
ML*8WP-_L"1\GHDSI].R2=_!.ZS41X86-\=?4$FPA2\N>@"*%-(D2.>(.2ZWC
M,)FJ!-]4TC@%'V*=G,L$+NP@,!.C?!YY25B.@W&P<SA@@:VBBQ$],]Z^=*JL
M)9\NA<L3;,YQH(VSX=F=S'7%<6-$Y3,4"8#7A!>EJR%FJ2'9.DFDM=+VHDD^
M ]Y\8OA\7@#[7>$S0LZU6\@[^%V^3V#]<DH.,MF [P V%"'+\M<1&=:#9C70
M%@&!!%6&*E7)7)7LY22O4YSLU?"R^\U.GWU=9=KIKITIEV20VF[90N0Y%3H'
M?.224E-#E4PX8K3@Y*\T(LNQLZ <@A(!+.E.648(CC^(2DOXD!)1<SJ,&41P
M(BQ(Y526" -&DU[P Q\= 5#G^%#25!2RZP'%ZP(!%3Z67%=M#6SAV XP),@P
MX#!X<2*L2LUS2.5R6L*0EJ[4E*-76R3*<9HJ%HYO )-LAGXT@]&(1D R/+O4
M$?YPJ@N(S$51"!QTWFX5J +\-7*1,1S+<JX(1HLD8XN(-(51+"NJ84%AH+F9
MH#91BDP3(=E,)FO>$(X3QF7&*]H<M4=#RK6^Y</-&"H84+2YY2WAIXR]T&ZQ
M#TR$8I^H0)\4V9DIY)H4GE-,:L-I!YWN!(H8+X1\Z%HHK^!J3G[YA/LS\'HU
M36(ZP90+K+PM]0S1,P4,>G"$/Q*&1)BWE(Z=P-[C+(APR04<J@,9/>ZRT?EM
MI!$(D#$"(R4H M<X[./C8N(_JLM".NPK4R[#[9:N,B1:7@"98ZC81AI"/@(_
MGZS9 #KT:%![P>QF5DB:#EG.4L252A1B"LD0=UGBK/HEQ#<V^F$X'%P?/S%R
M>M"ARQ_.KK\_'IV%7]NMB[>G9V]&PYOX^N3L\ONW\=^#M]=G/UU>Q-]^&EZ_
M.'X3?Q&%YE-R='$PEZ!L_1VOU81= H6:BOC:%XR<[574)=<.Q8]G6"G]@J0V
M!I&>(_&L-'=,,^RR%#(%0>)PY+,-!#(W660G("/A?%(3&'2]\*%FV3IWT6$!
M\7P*(:2\F> \M;3^TC'0HD(J]^@T5_##X=LCUO1P^^U1 $.XFATQJ;'A6.D>
M_;7+5^23[99O8KR#4G;0>K7Z-1,EH _@2 J3SYG/]T.*54;>*5U;//S07IL^
MDT).,&\U5*)D>!H^ER_@W@_T EO+H.EX\L3R%H0[J+.[L_.L]U"E)0%24G$B
MK1+HQ3</DN50O&ICP8QT &%F30!Z<!O$?YVS-4K)96A-8HQXNN!@&C[0'G10
M!#B\F(#9NH@X3@85F^VPL'$ B78KD/6_=B!&OG,)LX\E4G720.0"B.%NSG+F
MW\#A6YGIG"$9T8':RNPC5[<RP+<H;]>[<R:KC#,9QP(7@4[#= -'2#T)-FI<
M!_@")S#P/\3/$>)+=@]J@!@:F,CL%S1M&)U?\#Z30/)C(S:I7<U]%4) W'&G
MX,4M%Z125D@7)B 2P.ZSK%D*^@%6"0T+X;E#Z/!$P[$!4FA^IT"Z6 P\MQ T
M4:A4(#W=)$> K7*$!9-LN,(7A+?/2Q;^->*,02VP#O@-AF7 G?#-K27FBK &
M@\]8<Y=C9*"]1G.W-(=Y]V/11(%<K8+>-<L229MO]!U78;MUK[#2Y@!A*?%X
MK;[2Y@LPS]+))-N^UDDFM_R.*Z65-D_ J<$S_TX7NAAO_;OW5>7S_=1MMOI;
MMTOG2N;I/H!O*@_P_<\U,RML2]UN'*<?#H;?-S+#3EVG*WRR6[EF[^Y8.Z>+
M?7K.S\;:((<7STYRYD9]"+<Z5RD4N%K?SVNV>M##;<A\0/P8E?RV.Y9(?.A8
M>9U757K^@$:LYN\5N6*8;;9,,,97ZLW?,V3^NNK,O='G!ZO(X<G1\5C7+B#E
M1P>NGU?JZI#[,8'O(UJ$XL C"$H \4R=NBB4B$GP6(:D$I]/YY$<@X['N8[G
MW6%,M.@M^!G@,JT39WWQ1+43GFT_T.+TFFE$$!X'#VB;_60B#"8^/(!HMYH)
M1,X7&#R?8JH69Q&+X8$O;:I$*5-,XZ#P-M3"Z;I&YKY%>G!$T4P(@FKWA@,=
M-/]EEPL(VGB1HQ@H;F)TM\#)<S\M"&W'^D %6O"]5ACS#E0V3XW61CL>FPVD
M_Q4R>$[0C*L'+R\'+Q<3:7^4L5PMT96"];6W&9LFF8=!GZ [>",-'2"K)BFJ
MQJXH),]9E"UH<YSK!)5O1(F$IO!<KB;+"0CS<KTZ Z%D[O0M#Y1@//;A%JS&
MQ#?,/IG]\/ SL$\]F70=MU5 91Z9A FQ#981$XF"JD!C?6-G-5,8[.+/&%BS
M/_S2:*&?%'&,$[DSNV<E'-EINV&L@_.B_9.I'S@6#2D$0Z\-?%WI?,XM1#87
M>8T.F_O$1*6=M>,P]\_9&MP8FE)BW8SS!XT>K%M.>W0.7Q;:SP)82@R., WV
M@S$7\_OMT6PVZ]VRRI5O4GJP$S>/GZ^,?R3#ORB.GH?15?=":\\];SB^F5K9
M_R]8O=&A.^6PLPL;A,$"C_QX5-BD$;+6+&YWXNROFP<#+EH(SFM\58"OAO92
MH%F(4R?.)VY2P(O"$,3&&0^_O#+JCH/X!C!D?!M*%_@Q#6E^+7V"'"?<>;1;
M_;V]9\W]SL<56CN4'R^O/O+H&L8L:V,A/GTYM>&F*J9NT=QM_&I,U6XU]PG\
M.FP .MR +*<?J+OT@OPH%KBWN()@TBY0T,*L9[W7;HI4)^K>H(<?"D<8\3*;
M@;F_N9LQ2L9:%'LIWR5)/>D$Z,+3;*&)906;[WAZ7&K'W;L>LUX &:Y$2:8D
M#SP8<?WD'TW=6%CE%Z/VH80T_EB:%Q6GO-,YFA2C[&VP#E]6^@-[#_NZR3+]
M+)[G$W4>KV44C]/Q#O5+\3A\>;NWXC\+V&8S9@]'[(K=V#0/^#<X9L5OZ' #
M=@=UH[+^ #01X983\)N@FY9Q;NJ5RN*,+T;C-7]_'KYO0I&;<&]1MLL]3Q^7
M)=\T7<L*IV$KGW.X]W>ZK]#OYDW)84$W9Z?\_K4P\.'N,W_?W&<O++7ZU>[A
M:%4]SE%"L!^?_=XDR1,5;WQV!Z)"^PF.KX;ADJ0Y/?(5X 'AB]K& ;,8A))
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MW.;_%QO^HRS_?]K_ E!+ 0(4 Q0    ( *PU053-!4:5/P,   0,   1
M          "  0    !K<')X+3(P,C(P,3,Q+GAS9%!+ 0(4 Q0    ( *PU
M053YKCU/_PH  &R'   5              "  6X#  !K<')X+3(P,C(P,3,Q
M7VQA8BYX;6Q02P$"% ,4    " "L-4%4393G$5<'  #+6   %0
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8=&U02P4&      8 !@"* 0  &UL

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
